TEVA
Teva Pharmaceutical Industries Limited
Set alert
- YTD
- +34.86%
- 1 year
- +110.13%
- Open
- 41.17
- Prev close
- 41.47
- Mkt cap
- 49.09B
- Vol
- 7.36M
- Avg vol
- 5.49M
- EPS
- 0.60
- P/E
- 70.15
- Div yield
- 0.00%
More statistics
- Low
- 41.22
- High
- 42.59
- Forward P/E
- 13.58
- Beta
- 0.82
- Short ratio
- 4.40
- Inst. own
- 29.68%
- Dividend
- 0.00
- Ex-div date
- Nov 27, 2017
- Earnings
- Nov 3, 2026
- 50-d avg
- 38.98
- 200-d avg
- 34.53
- 1y target
- 47.58
Key statistics
- Market cap
- 48.92B
- Enterprise value
- 61.57B
- Trailing P/E
- 69.91
- Forward P/E
- 13.58
- PEG ratio
- 0.71
- Price / sales
- 2.83
- Price / book
- 6.30
- EPS (TTM)
- 0.60
- Beta
- 0.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 4.08%
- Revenue (TTM)
- 17.32B
- Revenue growth
- -0.80%
- Free cash flow
- 2.22B
- Total cash
- 3.66B
- Total debt
- 16.89B
- Return on equity
- 9.69%
- Shares outstanding
- 1.17B
- Short % of float
- 2.42%
- 50-day average
- 38.98
- 200-day average
- 34.53
Analyst view
Consensus: strong buy
- Target (low)
- 42.00
- Target (mean)
- 47.58
- Target (high)
- 55.00
- Strong buy4
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.7302.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | 0.72 | — | — | — |
| Jul 29, 2026 | Jun 30, 2026 | 0.08 | 0.02 | -0.06 | -75.00% |
| Apr 29, 2026 | Mar 31, 2026 | 0.50 | 0.53 | +0.03 | +6.00% |
| Jan 28, 2026 | Dec 31, 2025 | 0.65 | 0.96 | +0.31 | +47.69% |
| Nov 5, 2025 | Sep 30, 2025 | 0.68 | 0.78 | +0.10 | +14.71% |
| Jul 30, 2025 | Jun 30, 2025 | 0.63 | 0.66 | +0.03 | +4.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | Barclays | main | Overweight | Overweight |
| Oct 12, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 1, 2026 | TD Cowen | init | — | Buy |
| Sep 23, 2026 | Oppenheimer | init | — | Outperform |
| Sep 9, 2026 | Leerink Partners | init | — | Outperform |
| Sep 4, 2026 | UBS | main | Buy | Buy |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- tevapharm.com
News
- Teva: I Still See Upside After A Massive Rally
- Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
- What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
- Teva Pharmaceuticals International GmbH Acquires BioXcel Therapeutics' Assets For $57.5M Upfront Payment
- Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
- Baron Health Care Fund Q3 2026 Top Contributors And Detractors
- Teva Pharma And Sanofi Report Duvakitug Maintained Efficacy Through 44 Weeks In Ulcerative Colitis And Crohn's Disease
- Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47
- FDA Approves Teva's New Once-Monthly Schizophrenia Injection
- Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults
Your note
Sign in to keep a note on TEVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARER SOL J | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 448,011 |
| CRANE ROSEMARY A | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 127,739 |
| ELSTEIN AMIR | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 2,118,460 |
| FOX CHRISTINE | Officer | Sale | Mar 3, 2026 | 75,010 |
| FRANCIS RICHARD D | Chief Executive Officer | Sale | Jun 4, 2026 | 1,177,530 |
| HUGHES ERIC A | Officer | Sale | Aug 2, 2026 | 134,877 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.48% | 63,894,301 | 2.68B | Jun 29, 2026 |
| Harel Insurance Investments & Financial Services Ltd. | 4.13% | 48,138,805 | 2.02B | Jun 29, 2026 |
| Phoenix Financial Ltd. | 3.68% | 42,933,367 | 1.80B | Jun 29, 2026 |
| WCM Investment Management, LLC | 3.55% | 41,315,232 | 1.73B | Jun 29, 2026 |
| Clal Insurance Enterprises Holdings Ltd | 3.48% | 40,596,506 | 1.70B | Jun 29, 2026 |
| Menora Mivtachim Holdings Ltd. | 3.42% | 39,854,383 | 1.67B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | 1.47% | 17,083,534 | 716.57M | Jul 30, 2026 |
| INVESTMENT MANAGERS SERIES TRUST-WCM Focused International Growth Fund | 1.14% | 13,253,660 | 555.92M | Jun 29, 2026 |
| New Economy Fund | 1.06% | 12,327,600 | 517.08M | Sep 29, 2026 |
| VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund | 0.97% | 11,344,396 | 475.84M | Jun 29, 2026 |
| iShares Trust-iShares Core MSCI EAFE ETF | 0.76% | 8,854,390 | 371.40M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity Intl Fd. | 0.40% | 4,663,445 | 195.61M | Aug 30, 2026 |